P. Mulvenna

2.3k total citations · 1 hit paper
18 papers, 681 citations indexed

About

P. Mulvenna is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, P. Mulvenna has authored 18 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in P. Mulvenna's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Brain Metastases and Treatment (7 papers). P. Mulvenna is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Brain Metastases and Treatment (7 papers). P. Mulvenna collaborates with scholars based in United Kingdom, Australia and Austria. P. Mulvenna's co-authors include Ruth E. Langley, Matthew Nankivell, Richard Stephens, Corinne Faivre‐Finn, Mahesh Parmar, Cheryl Pugh, Rachael Barton, Barbara Moore, N. Bayman and Tanya Holt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Thorax.

In The Last Decade

P. Mulvenna

15 papers receiving 657 citations

Hit Papers

Dexamethasone and supportive care with or without whole b... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
    2016 453 citations P. Mulvenna, Matthew Nankivell et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Mulvenna United Kingdom 10 590 433 248 88 83 18 681
N. Bayman United Kingdom 15 753 1.3× 456 1.1× 187 0.8× 89 1.0× 131 1.6× 48 950
O. Agboola Canada 10 228 0.4× 142 0.3× 124 0.5× 75 0.9× 56 0.7× 18 429
M. Hochstenbag Netherlands 10 429 0.7× 284 0.7× 34 0.1× 109 1.2× 45 0.5× 27 552
Neil R. Parikh United States 10 219 0.4× 81 0.2× 88 0.4× 50 0.6× 33 0.4× 24 321
Marie-Ange Massiani France 13 320 0.5× 355 0.8× 22 0.1× 40 0.5× 49 0.6× 23 514
Lucia Masiero Italy 7 148 0.3× 56 0.1× 153 0.6× 147 1.7× 70 0.8× 13 410
Drexell H. Boggs United States 11 163 0.3× 117 0.3× 35 0.1× 25 0.3× 90 1.1× 30 315
Romain Rivoirard France 11 92 0.2× 125 0.3× 46 0.2× 22 0.3× 51 0.6× 53 307
J. McAleese United Kingdom 15 282 0.5× 95 0.2× 50 0.2× 65 0.7× 77 0.9× 48 478
Michael A. Izard Australia 9 218 0.4× 79 0.2× 30 0.1× 27 0.3× 43 0.5× 19 354

Countries citing papers authored by P. Mulvenna

Since Specialization
Citations

This map shows the geographic impact of P. Mulvenna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Mulvenna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Mulvenna more than expected).

Fields of papers citing papers by P. Mulvenna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Mulvenna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Mulvenna. The network helps show where P. Mulvenna may publish in the future.

Co-authorship network of co-authors of P. Mulvenna

This figure shows the co-authorship network connecting the top 25 collaborators of P. Mulvenna. A scholar is included among the top collaborators of P. Mulvenna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Mulvenna. P. Mulvenna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Iqbal, Muhammad Shahid, Fiona McDonald, Philip J. Atherton, et al.. (2020). Sequential chemotherapy followed by radical thoracic radiotherapy (50 Gy in 25 fractions) in limited stage small cell lung cancer. ecancermedicalscience. 14. 1019–1019.
2.
Iqbal, Muhammad Shahid, R. McMenemin, Philip J. Atherton, et al.. (2018). Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review. Clinical Oncology. 31(2). e1–e10. 14 indexed citations
3.
Mulvenna, P., Fiona McDonald, Helen Turnbull, et al.. (2018). Hypofractionated concurrent chemoradiation in non-small cell lung cancer (NSCLC): efficacy and toxicity of the SOCCAR trial regime in real world practice. Lung Cancer. 115. S64–S64. 1 indexed citations
4.
Hogarth, Linda, Miranda Patterson, David Jamieson, et al.. (2017). P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S829–S830.
5.
Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet. 388(10055). 2004–2014. 453 indexed citations breakdown →
6.
Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2015). Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).. Journal of Clinical Oncology. 33(15_suppl). 8005–8005. 21 indexed citations
7.
Stephens, Richard, Ruth E. Langley, P. Mulvenna, et al.. (2014). Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?. Lung Cancer. 85(2). 116–118. 9 indexed citations
8.
Khan, Fazal, Christian H. Ottensmeier, Sanjay Popat, et al.. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer. 50(10). 1717–1721. 10 indexed citations
9.
Preusser, Matthias, Frank Winkler, Laurence Collette, et al.. (2012). Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. European Journal of Cancer. 48(18). 3439–3447. 37 indexed citations
10.
11.
Wilson, James M., et al.. (2012). Effect of thoracic radiotherapy in extensive-disease small cell lung cancer on progression-free and overall survival: A retrospective review.. Journal of Clinical Oncology. 30(15_suppl). e17519–e17519. 1 indexed citations
12.
13.
14.
15.
Mulvenna, P., A. Wright, & T.J. Podd. (1999). Life-Threatening Tamoxifen-Induced Hypercalcaemia. Clinical Oncology. 11(3). 193–195. 2 indexed citations
16.
Mulvenna, P., et al.. (1995). Lymphangiosarcomata - experience in a lymphoedema clinic. Palliative Medicine. 9(1). 55–59. 5 indexed citations
17.
Ong, Edmund, P. Mulvenna, & Kevin Webb. (1991). Varicella-zoster Infection in Adults with Cystic Fibrosis: Role of Acyclovir. Scandinavian Journal of Infectious Diseases. 23(3). 283–285. 19 indexed citations
18.
Bilton, Diana, et al.. (1990). Life threatening haemoptysis in cystic fibrosis: an alternative therapeutic approach.. Thorax. 45(12). 975–976. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. Bayman Breakdown of academic impact, for papers by O. Agboola Breakdown of academic impact, for papers by M. Hochstenbag Breakdown of academic impact, for papers by Neil R. Parikh Breakdown of academic impact, for papers by Marie-Ange Massiani Breakdown of academic impact, for papers by Lucia Masiero Breakdown of academic impact, for papers by Drexell H. Boggs Breakdown of academic impact, for papers by Romain Rivoirard Breakdown of academic impact, for papers by J. McAleese Breakdown of academic impact, for papers by Michael A. Izard
Rankless by CCL
2026